News
OBIO
5.95
0.00%
0.00
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 15h ago
Strength Seen in Orchestra BioMed Holdings, Inc. (OBIO): Can Its 5.2% Jump Turn into More Strength?
NASDAQ · 4d ago
Weekly Report: what happened at OBIO last week (0914-0918)?
Weekly Report · 4d ago
Orchestra BioMed Holdings Is Maintained at Buy by B. Riley Securities
Dow Jones · 09/15 16:20
Orchestra BioMed Holdings Price Target Raised to $11.00/Share From $10.00 by B. Riley Securities
Dow Jones · 09/15 16:20
Orchestra BioMed receives $6.1M milestone payment from Haemonetics
TipRanks · 09/15 12:55
Press Release: Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics
Dow Jones · 09/15 12:30
Orchestra BioMed price target raised to $11 from $10 at B. Riley
TipRanks · 09/15 12:20
Biotech Stocks At 52-Week Highs - TXG, OBIO, AVAH, OSCR, LFST, TVTX
NASDAQ · 09/14 13:37
Weekly Report: what happened at OBIO last week (0907-0911)?
Weekly Report · 09/14 09:21
This Copart Analyst Turns Bullish; Here Are Top 2 Upgrades For Friday
Benzinga · 09/11 17:36
Biotech Stocks At 52-Week Highs - OBIO, AVAH, TVTX, TXG, LFST
NASDAQ · 09/11 09:37
5 Biotech Stocks In Spotlight: Tenon Medical, AEON Biopharma, Silexion, Orchestra BioMed & Indaptus
NASDAQ · 09/10 18:49
Crude Oil Surges 6%; Macy’s Shares Fall After Q2 Results
Benzinga · 09/10 16:33
Wealthfront, Orchestra Biomed, AeroVironment And Other Big Stocks Moving Higher On Thursday
Benzinga · 09/10 14:02
This Meta Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Benzinga · 09/10 12:53
Orchestra BioMed Holdings Price Target Announced at $10.00/Share by BTIG
Dow Jones · 09/10 10:06
Orchestra BioMed Holdings Raised to Buy From Neutral by BTIG
Dow Jones · 09/10 10:06
BTIG Upgrades Orchestra BioMed Hldgs to Buy, Announces $10 Price Target
Benzinga · 09/10 09:56
Orchestra BioMed upgraded to Buy from Neutral at BTIG
TipRanks · 09/10 09:45
More
Webull provides a variety of real-time OBIO stock news. You can receive the latest news about Orchestra BioMed Holdings Inc through multiple platforms. This information may help you make smarter investment decisions.
About OBIO
Orchestra BioMed Holdings, Inc. is a biomedical innovation company. The Company’s lead product candidates include Atrioventricular Interval Modulation (AVIM) therapy for the treatment of hypertension (HTN), the leading risk factor for death worldwide and the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. The Company develops bioelectronic therapies based on patented Cardiac Neuromodulation Therapy (CNT) technology. The AVIM is a bioelectronic therapy candidate designed to substantially and persistently lower blood pressure. Its Virtue SAB is a proprietary drug/device combination product candidate for the treatment of artery disease that is designed to deliver a proprietary, investigational, extended-release formulation of sirolimus (SirolimusEFR) to the vessel wall during balloon angioplasty without the need for balloon coating or a permanent implant.